GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Diva Laboratories Ltd (ROCO:4153) » Definitions » Cyclically Adjusted Revenue per Share

Diva Laboratories (ROCO:4153) Cyclically Adjusted Revenue per Share : NT$20.20 (As of Mar. 2025)


View and export this data going back to 2013. Start your Free Trial

What is Diva Laboratories Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Diva Laboratories's adjusted revenue per share for the three months ended in Mar. 2025 was NT$3.495. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is NT$20.20 for the trailing ten years ended in Mar. 2025.

During the past 12 months, Diva Laboratories's average Cyclically Adjusted Revenue Growth Rate was -9.50% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -5.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Diva Laboratories was -2.90% per year. The lowest was -5.10% per year. And the median was -4.00% per year.

As of today (2025-05-29), Diva Laboratories's current stock price is NT$42.00. Diva Laboratories's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was NT$20.20. Diva Laboratories's Cyclically Adjusted PS Ratio of today is 2.08.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Diva Laboratories was 2.38. The lowest was 0.88. And the median was 1.45.


Diva Laboratories Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Diva Laboratories's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Diva Laboratories Cyclically Adjusted Revenue per Share Chart

Diva Laboratories Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.43 24.12 23.85 22.35 20.60

Diva Laboratories Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.32 21.84 21.14 20.60 20.20

Competitive Comparison of Diva Laboratories's Cyclically Adjusted Revenue per Share

For the Diagnostics & Research subindustry, Diva Laboratories's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Diva Laboratories's Cyclically Adjusted PS Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Diva Laboratories's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Diva Laboratories's Cyclically Adjusted PS Ratio falls into.


;
;

Diva Laboratories Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Diva Laboratories's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=3.495/134.9266*134.9266
=3.495

Current CPI (Mar. 2025) = 134.9266.

Diva Laboratories Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 9.551 100.684 12.799
201509 8.124 100.392 10.919
201512 7.184 99.792 9.713
201603 6.683 100.470 8.975
201606 7.180 101.688 9.527
201609 6.758 101.861 8.952
201612 5.791 101.863 7.671
201703 4.769 102.862 6.256
201706 6.725 103.349 8.780
201709 4.427 104.136 5.736
201712 4.471 104.011 5.800
201803 3.048 105.290 3.906
201806 2.880 106.317 3.655
201809 2.530 106.507 3.205
201812 2.308 105.998 2.938
201903 3.201 107.251 4.027
201906 3.238 108.070 4.043
201909 2.893 108.329 3.603
201912 1.471 108.420 1.831
202003 2.136 108.902 2.646
202006 2.879 108.767 3.571
202009 3.494 109.815 4.293
202012 2.550 109.897 3.131
202103 2.567 111.754 3.099
202106 2.890 114.631 3.402
202109 3.436 115.734 4.006
202112 3.279 117.630 3.761
202203 3.283 121.301 3.652
202206 3.870 125.017 4.177
202209 3.967 125.227 4.274
202212 5.014 125.222 5.403
202303 4.230 127.348 4.482
202306 3.967 128.729 4.158
202309 3.522 129.860 3.659
202312 3.474 129.419 3.622
202403 3.741 131.776 3.830
202406 3.738 132.554 3.805
202409 3.340 133.029 3.388
202412 3.772 133.157 3.822
202503 3.495 134.927 3.495

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Diva Laboratories  (ROCO:4153) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Diva Laboratories's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=42.00/20.20
=2.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Diva Laboratories was 2.38. The lowest was 0.88. And the median was 1.45.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Diva Laboratories Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Diva Laboratories's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Diva Laboratories Business Description

Traded in Other Exchanges
N/A
Address
Zhongshan Road, 9F, No. 351, Sector 2, Zhonghe District, New Taipei City, TWN, 235
Diva Laboratories Ltd is a Taiwan-based company that engages in the sale, manufacturing, and development of medical equipment and computer-related devices. It offers endo/surgical displays; color displays for radiology and medical imaging services; touch displays; and original design manufacturing and original equipment manufacturing solutions.

Diva Laboratories Headlines

No Headlines